The HIV-infected adolescent

Current Infectious Disease Reports

Volumn 12, Issue 1, 2010, Pages 63-70

  Ross, Allison C ^a   Camacho Gonzalez, Andres ^a   Henderson, Sheryl ^a   Abanyie, Francisca ^a   Chakraborty, Rana ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adolescent; Antiretrovirals; Epidemiology; HIV AIDS; Treatment

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; ANTIRETROVIRUS AGENT; ATAZANAVIR; DARUNAVIR; EFAVIRENZ; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ETRAVIRINE; FOSAMPRENAVIR; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR; MARAVIROC; NEVIRAPINE; PLACEBO; PROTEINASE INHIBITOR; RALTEGRAVIR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR; TIPRANAVIR;

ADOLESCENT; ADOLESCENT HEALTH; ANEMIA; ANTIVIRAL ACTIVITY; CHILD BEHAVIOR; CLINICAL PROTOCOL; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; FANCONI RENOTUBULAR SYNDROME; GASTROINTESTINAL SYMPTOM; HARM REDUCTION; HIGH RISK BEHAVIOR; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; LIPOATROPHY; LOW DRUG DOSE; MENTAL HEALTH CARE; NEPHROTOXICITY; OSTEOPOROSIS; PATIENT COMPLIANCE; RASH; REVIEW; SOCIAL PSYCHOLOGY; TREATMENT PLANNING;

EID: 77249105335     PISSN: 15233847     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11908-009-0077-4     Document Type: Review

References (49)

1. Centers for Disease Control and Prevention 2009 HIV testing among high school students-United States, 2007 MMWR Morb Mortal Wkly Rep 58 665 668
2. HI Hall R Song P Rhodes, et al. 2008 Estimation of HIV incidence in the United States JAMA 300 520 529 10.1001/jama.300.5.520 1:CAS:528: DC%2BD1cXps1ygtrY%3D 18677024
3. L Gavin AP MacKay K Brown, et al. 2009 Sexual and reproductive health of persons aged 10-24 years-United States, 2002-2007 MMWR Surveill Summ 58 1 58 19609250 This article provides the latest epidemiologic report for this age group.
4. •• Panel on Antiretroviral Guidelines for Adults and Adolescents: Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents, Department of Health and Human Services November 3, 2008:1-139. Available at: http://www.aidsinfo.nih.gov/ContentFiles/ adultandadolescentGL.pdf. Accessed October 2009. This URL provides frequently updated guidelines on antiretroviral therapy in HIV-infected adolescents.
5. RP Walensky AD Paltiel E Losina, et al. 2006 The survival benefits of AIDS treatment in the United States J Infect Dis 194 11 19 10.1086/505147 16741877 (Pubitemid 43911920)
6. + T-cell counts. (Pubitemid 351590049)
7. + count-guided interruption of antiretroviral treatment N Engl J Med 355 2283 2296 10.1056/NEJMoa062360 1:STN:280:DC%2BD28npvVSntw%3D%3D 17135583 This article describes a major clinical trial that showed how intermittent, CD4-guided ART significantly increases the risk of opportunistic disease and all-cause mortality, as compared with continuous ART. (Pubitemid 44837777)
8. + cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression Clin Infect Dis 44 441 446 10.1086/510746 17205456 (Pubitemid 46147630)
9. + T-cell count of 351 to 500, deferral of ART was associated with a 69% increase in the risk of death, as compared with early initiation of therapy.
10. + T-cell counts ameliorates the risk of three important adverse conditions associated with HIV infection and that are frequently attributed to toxicity-related side effects of antiretrovirals. (Pubitemid 351619366)
11. J Uy C Armon K Buchacz, et al. 2009 Initiation of HAART at higher CD4 cell counts is associated with a lower frequency of antiretroviral drug resistance mutations at virologic failure J Acquir Immune Defic Syndr 51 450 453 10.1097/QAI.0b013e3181acb630 19474757
12. A Calmy A Gayet-Ageron F Montecucco, et al. 2009 HIV increases markers of cardiovascular risk: results from a randomized, treatment interruption trial AIDS 23 929 939 10.1097/QAD.0b013e32832995fa 1:CAS:528:DC%2BD1MXltlKqsrY%3D 19425222 This study demonstrates that HIV infection is associated with increased inflammatory markers that have been linked to increased cardiovascular disease risk in the general population.
13. VA Triant 2009 JB Meigs, SK Grinspoon: Association of C-reactive protein and HIV infection with acute myocardial infarction J Acquir Immune Defic Syndr 51 268 273 10.1097/QAI.0b013e3181a9992c 1:CAS:528:DC%2BD1MXns1ertb8%3D 19387353 This article shows that patients with both HIV and C-reactive protein are at increased risk of myocardial infarction.
14. AC Weintrob J Giner P Menezes, et al. 2003 Infrequent diagnosis of primary human immunodeficiency virus infection: missed opportunities in acute care settings Arch Intern Med 163 2097 2100 10.1001/archinte.163.17.2097 14504125 (Pubitemid 37151254)
15. D Klein LB Hurley D Merrill, et al. 2003 Review of medical encounters in the 5 years before a diagnosis of HIV-1 infection: implications for early detection J Acquir Immune Defic Syndr 32 143 152 12571523
16. + T cell responses associated with control of viremia Science 278 1447 1450 10.1126/science.278.5342.1447 1:CAS:528: DyaK2sXnsVGlsL0%3D 9367954 (Pubitemid 27509814)
17. A Zolopa J Andersen W Powderly, et al. 2009 Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial PLoS One 4 e5575 10.1371/journal.pone.0005575 19440326 This article shows that waiting to complete OI treatment before initiating ART appears to be associated with a higher risk of AIDS-related disease progression and/or death without any significant benefit in terms of safety or virologic response.
18. NR Gandhi AP Moll U Lalloo, et al. 2009 Successful integration of tuberculosis and HIV treatment in rural South Africa: the Sizonq'oba study J Acquir Immune Defic Syndr 50 37 43 10.1097/QAI.0b013e31818ce6c4 19295333 This article shows a model of concurrent treatment of TB/HIV coinfection achieving high levels of adherence and excellent TB and HIV outcomes, with few adverse events or immune reconstitution reactions.
19. GK Robbins V De Gruttola RW Shafer, et al. 2003 Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection N Engl J Med 349 2293 2303 10.1056/NEJMoa030264 1:CAS:528:DC%2BD3sXpvVChtLk%3D 14668455 (Pubitemid 37509737)
20. R Chou R Fu LH Huffman, et al. 2006 Initial highly active antiretroviral therapy with a protease inhibitor versus a non-nucleoside reverse transcriptase inhibitor: discrepancies between direct and indirect meta-analyses Lancet 368 1503 1515 10.1016/S0140-6736(06)69638-4 1:CAS:528:DC%2BD28XhtFent7jO 17071284 (Pubitemid 44634694)
21. JA Bartlett J Johnson G Herrera, et al. 2006 An updated systematic overview of triple combination therapy in antiretroviral-naive HIV-infected adults AIDS 20 2051 2064 10.1097/01.aids.0000247578.08449.ff 1:CAS:528:DC%2BD28XhtV2rsrnF 17053351 (Pubitemid 44611058)
22. JB Purdy RI Gafni JC Reynolds, et al. 2008 Decreased bone mineral density with off-label use of tenofovir in children and adolescents infected with human immunodeficiency virus J Pediatr 152 582 584 10.1016/j.jpeds.2007.12.020 1:CAS:528:DC%2BD1cXjtl2ntLg%3D 18346519 This article reflects the need for a better understanding of the effects of tenofovir on bone mineral density.
23. F Pulido V Estrada JG Baril, et al. 2009 Long-term efficacy and safety of fosamprenavir plus ritonavir versus lopinavir/ritonavir in combination with abacavir/lamivudine over 144 weeks HIV Clin Trials 10 76 87 10.1310/hct1002-76 1:STN:280:DC%2BD1Mzot1GksQ%3D%3D 19487177
24. JM Molina J Andrade-Villanueva J Echevarria, et al. 2008 Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study Lancet 372 646 645 10.1016/S0140-6736(08)61081-8 1:CAS:528:DC%2BD1cXhtVagu7jM 18722869
25. Mills AM, Nelson M, Jayaweera D, et al.: Once-daily darunavir/ritonavir ce-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis. AIDS 2009, 23:1679-1688.
26. C Torti G Lapadula A Antinori, et al. 2009 Hyperbilirubinemia during atazanavir treatment in 2, 404 patients in the Italian atazanavir expanded access program and MASTER Cohorts Infection 37 244 249 1:CAS:528: DC%2BD1MXns1Cjt74%3D 19471856
27. E DeJesus G Herrera E Teofilo, et al. 2004 Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults Clin Infect Dis 39 1038 1046 10.1086/424009 1:CAS:528:DC%2BD2cXptFKjs7g%3D 15472858 (Pubitemid 39313463)
28. S Mallal D Nolan C Witt, et al. 2002 Association between presence of HLA-B5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir Lancet 359 727 732 10.1016/S0140- 6736(02)07873-X 1:CAS:528:DC%2BD38XhvVWhsbY%3D 11888582 (Pubitemid 34215071)
29. Sax P, Tierney C, Collier A, et al.: ACTG 5202: shorter time to virologic failure with ABC/3TC than tenofovir/FTC in treatment-naïve subjects with HIV RNA >100,000 [abstract THAB0303]. Presented at the 17th International AIDS Conference. Mexico City, Mexico; August 3-8, 2008
30. M Markowitz BY Nguyen E Gotuzzo, et al. 2009 Sustained antiretroviral effect of raltegravir after 96 weeks of combination therapy in treatment-naive patients with HIV-1 infection J Acquir Immune Defic Syndr 52 350 356 10.1097/QAI.0b013e3181b064b0 1:CAS:528:DC%2BD1MXhtlegsb7I 19648823
31. JL Lennox E Dejesus A Lazzarin, et al. 2009 Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial [see comment]. [Erratum in Lancet 2009, 374:786.] Lancet 374 796 806 10.1016/S0140-6736(09)60918-1 1:CAS:528:DC%2BD1MXhtV2ksLnL 19647866 The authors report an investigation of integrase inhibitors for treatment-naive patients.
32. C Katlama R Esposito JM Gatell, et al. 2007 Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1 AIDS 21 395 402 10.1097/QAD.0b013e328013d9d7 1:CAS:528:DC%2BD2sXhslCnu7s%3D 17301557 (Pubitemid 46263249)
33. JD Reeves AJ Piefer 2005 Emerging drug targets for antiretroviral therapy Drugs 65 1747 1766 10.2165/00003495-200565130-00002 1:CAS:528: DC%2BD2MXhtFeisr7L 16114975 (Pubitemid 41247948)
34. P Dorr M Westby S Dobbs, et al. 2005 Maraviroc (UK-427, 857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity Antimicrob Agents Chemother 49 4721 4732 10.1128/AAC.49.11.4721-4732. 2005 1:CAS:528:DC%2BD2MXht1Siu7rM 16251317 (Pubitemid 41552605)
35. RT Steigbigel DA Cooper PN Kumar, et al. 2008 Raltegravir with optimized background therapy for resistant HIV-1 infection N Engl J Med 359 339 354 10.1056/NEJMoa0708975 18650512
36. JV Madruga P Cahn B Grinsztejn, et al. 2007 Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial Lancet 370 29 38 10.1016/S0140-6736(07)61047-2 1:CAS:528:DC%2BD2sXnsFWmtLs%3D 17617270 The study authors describe an investigation of the use of etravirine in treatment-experienced patients. (Pubitemid 47017466)
37. A Lazzarin T Campbell B Clotet, et al. 2007 Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial Lancet 370 39 48 10.1016/S0140-6736(07)61048-4 1:CAS:528:DC%2BD2sXnsFWmtLg%3D 17617271 The authors report on an investigation of the use of etravirine in treatment-experienced patients. (Pubitemid 47017467)
38. D Descamps P Flandre V Calvez, et al. 2000 Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. Trilege (Agence Nationale de Recherches sur le SIDA 072) Study Team JAMA 283 205 211 10.1001/jama.283.2.205 1:CAS:528:DC%2BD3cXnsVOhtg%3D%3D 10634336
39. DA Murphy CM Wilson SJ Durako, et al. 2001 Antiretroviral medication adherence among the REACH HIV-infected adolescent cohort in the USA AIDS Care 13 27 40 10.1080/09540120020018161 1:STN:280:DC%2BD3M7lsFSitw%3D%3D 11177463 (Pubitemid 32125499)
40. •Murphy DA, Lam P, Naar-King S, et al.: Health literacy and antiretroviral adherence among HIV-infected adolescents. Patient Educ Couns 2009, E-pub ahead of print. This article provides evidence that health literacy does not improve medication adherence in adolescents as it does in adults.
41. Peralta L, Metcalf M, LaGrange R, et al.: Innovative use of electronic technology for HIV medication adherence among urban youth [abstract B11260]. Presented at the 15th International Conference on AIDS. Bangkok, Thailand; July 11-16, 2004.
42. F Lori R Maserati A Foli, et al. 2000 Structured treatment interruptions to control HIV-1 infection Lancet 355 287 288 10.1016/S0140-6736(99)03515-1 1:STN:280:DC%2BD3c7jslGntw%3D%3D 10675080 (Pubitemid 30068525)
43. J Martinez SG Hosek RA Carleton 2009 Screening and assessing violence and mental health disorders in a cohort of inner city HIV-positive youth between 1998-2006 AIDS Patient Care STDS 23 469 475 10.1089/apc.2008.0178 19519231 This article demonstrates the high degree of psychiatric comorbidities in HIV-infected adolescents.
44. SM Wood SS Shah AP Steenhoff RM Rutstein 2009 The impact of AIDS diagnoses on long-term neurocognitive and psychiatric outcomes of surviving adolescents with perinatally acquired HIV AIDS 23 1859 1865 10.1097/QAD. 0b013e32832d924f 19584705 The authors of this article provide evidence that advanced HIV disease in children affects later neurocognitive and psychiatric outcomes in adolescents.
45. CA Mellins E Brackis-Cott C Dolezal EJ Abrams 2006 Psychiatric disorders in youth with perinatally acquired human immunodeficiency virus infection Pediatr Infect Dis J 25 432 437 10.1097/01.inf.0000217372.10385.2a 16645508 (Pubitemid 43755098)
46. DK Eaton L Kann S Kinchen, et al. 2008 Youth risk behavior surveillance-United States, 2007 MMWR Surveill Summ 57 1 131 18528314 These epidemiologic data show the prevalence of high-risk sexual behavior and substance use among youth.
47. DT Fleming JN Wasserheit 1999 From epidemiological synergy to public health policy and practice: the contribution of other sexually transmitted diseases to sexual transmission of HIV infection Sex Transm Infect 75 3 17 10.1136/sti.75.1.3 1:STN:280:DyaK1MznslCntg%3D%3D 10448335
48. American Academy of Pediatrics 2002 American Academy of Family Physicians, and American College of Physicians-American Society of Internal Medicine: A consensus statement on health care transitions for young adults with special health care needs Pediatrics 110 6 Pt 2 1304 1306
49. DS Rosen RW Blum M Britto, et al. 2003 Transition to adult health care for adolescents and young adults with chronic conditions: position paper of the Society for Adolescent Medicine J Adolesc Health 33 309 311 10.1016/S1054- 139X(03)00208-8 14519573